Advertisement

Topics

Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

12:26 EDT 30 Jul 2017 | SCRIP

Safety of Dynavax's hepatitis B vaccine gets thumbs up from US FDA advisory committee, but panel remained concern that postmarketing...

      

Related Stories

 

Original Article: Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

NEXT ARTICLE

More From BioPortfolio on "Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study"

Quick Search
Advertisement
 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...